J&J receives three subpoenas

Share this article:
Johnson & Johnson has received separate subpoenas from US Attorney’s Offices in Philadelphia, Boston and San Francisco related to marketing of three prescription drugs. The drugs at issue are schizophrenia and bipolar treatment Risperdal, marketed by Janssen, epilepsy treatment Topamax by Ortho-McNeil and heart-failure drug Natrecor by Scios. The investigations have been previously disclosed. The latest subpoenas seek information concerning corporate supervision and oversight of the J&J subsidiaries, which sell the drugs. The new subpoenas arrived at J&J’s corporate headquarters late last week, according to published reports. J&J said it plans to cooperate in responding to the subpoenas.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.